Xenon Pharmaceuticals
XENE
219 hedge funds and large institutions have $3.39B invested in Xenon Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 35 funds opening new positions, 68 increasing their positions, 71 reducing their positions, and 20 closing their positions.
75% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 20
30% more capital invested
Capital invested by funds: $2.6B → $3.39B (+$783M)
6% more funds holding
Funds holding: 206 → 219 (+13)
1.02% more ownership
Funds ownership: 108.34% → 109.36% (+1%)
4% less repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 71
10% less funds holding in top 10
Funds holding in top 10: 10 → 9 (-1)
28% less call options, than puts
Call options by funds: $10.2M | Put options by funds: $14.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$50.5M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$29.6M |
| 3 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$18.4M |
| 4 |
Millennium Management
New York
|
+$17.7M |
| 5 |
CP
Caligan Partners
New York
|
+$15.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VPC
Vestal Point Capital
New York
|
-$31.7M |
| 2 |
BlackRock
New York
|
-$20.9M |
| 3 |
O
OrbiMed
New York
|
-$18.6M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$16M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$14.4M |
XENE Hedge Fund Activity: Q3 2025 in Review
219 of the 7,641 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q3 2025, worth a combined $3.39B — up 30% from $2.6B a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new XENE positions and 20 closed out — a net gain of 15 holders — while 68 added to existing stakes and 71 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $50.5M. The largest seller was Vestal Point Capital, cutting an estimated $31.7M.
- 219 institutional investors held Xenon Pharmaceuticals (XENE) as of Q3 2025, up from 206 in Q2 2025.
- Funds reported $3.39B of Xenon Pharmaceuticals stock for Q3 2025, up 30% quarter-over-quarter.
- 35 funds opened new Xenon Pharmaceuticals positions in Q3 2025 and 20 closed out, a net change of +15 holders.
- The largest Xenon Pharmaceuticals buyer in Q3 2025 was Wellington Management Group, an estimated $50.5M added.
- The largest Xenon Pharmaceuticals seller in Q3 2025 was Vestal Point Capital, an estimated $31.7M sold.
Based on aggregated 13F filings for Q3 2025.